Structure-guided deimmunisation of Fel d 1 suppresses allergic effector functions ex vivo

This study demonstrates that a structure-guided computational approach successfully deimmunized the major cat allergen Fel d 1 by introducing specific mutations like K29G, which significantly reduced IgE reactivity and basophil activation while preserving cellular function, thereby offering a promising strategy for safer immunotherapies and the development of hypoallergenic cats.

The Gist

Imagine you have a friend who loves cats but can't be around them because their immune system goes into a panic attack whenever it smells cat dander. This panic is caused by a specific protein called Fel d 1, which is like a "danger signal" hidden in the cat's saliva and fur. For most allergic people, this protein is the main villain, triggering sneezing, itching, and breathing trouble.

Currently, the only way to treat this is to slowly expose the person to the real cat protein (immunotherapy), hoping their body learns to ignore it. But this is risky (it can cause severe reactions) and takes years. Another idea is to just delete the protein entirely from the cat using gene editing, but scientists worry: What if the cat actually needs this protein to stay healthy?

This paper presents a clever "Goldilocks" solution: Instead of deleting the protein or using the dangerous real version, the team engineered a "hypoallergenic" (low-allergy) version of the Fel d 1 protein. They kept the protein's shape so the cat stays healthy, but they changed a few tiny letters in its code so the human immune system no longer recognizes it as a threat.

Here is how they did it, broken down into simple steps:

1. The Blueprint: Finding the "Achilles' Heel"

Think of the Fel d 1 protein as a complex, 3D puzzle piece. The human immune system has "guards" (antibodies) that latch onto specific spots on this puzzle to sound the alarm.

• The Strategy: The scientists used a computer to map out exactly where these guards latch on. They found that some spots were "hotspots" where both the alarm-sounding guards (IgE antibodies) and the command centers (T-cells) gathered.
• The Analogy: Imagine the protein is a castle. The immune system is an army trying to break in. The scientists found the specific drawbridges (epitopes) the army uses to enter. Instead of blowing up the whole castle (which might hurt the cat), they decided to build fake drawbridges that look the same but are too slippery for the army to climb.

2. The Design: Swapping the Bricks

The team designed 30 different versions of the protein. They took the "hotspot" areas and swapped out a single amino acid (a tiny building block of the protein) for a different one.

• The Result: They created a library of "disguised" proteins. Most of them still looked like the original to the cat, but the human immune system couldn't grab onto them anymore.
• The Winner: One specific version, called K29G, was the champion. It was like changing a single key on a lock; the lock still works for the cat, but the human key no longer fits.

3. The Test: The "Basophil" Dance Party

To see if their new protein actually worked, they didn't just look at it; they tested it on human blood cells.

• The Setup: They took blood from people with severe cat allergies. Inside this blood are "basophils," which are like tiny soldiers waiting for the signal to attack.
• The Experiment: They exposed these soldiers to the real cat protein and the new K29G protein.
• The Outcome:
  • Real Protein: The soldiers went wild, jumping up and down (activating) and releasing chemicals that cause allergies.
  • K29G Protein: The soldiers stayed calm. They didn't recognize the protein as a threat, so they didn't attack. The "dance party" was cancelled.

4. The Future: Editing the Cat

The ultimate goal isn't just to make a pill; it's to make hypoallergenic cats.

• The Challenge: You can't just inject a cat with the new protein; you need the cat to make it naturally.
• The Solution: The team used CRISPR (a gene-editing tool) to edit the DNA of cat cells in a lab dish. They swapped the "dangerous" gene for the "safe" K29G version.
• The Safety Check: Before releasing these cats into the world, they had to make sure the edit didn't hurt the cat. They watched the edited cells grow and divide.
• The Verdict: The edited cells grew just as fast and healthy as normal cat cells. The "safe" protein didn't break the cat's internal machinery.

Why This Matters

This paper is a major step forward because it combines computer design with gene editing to solve a problem that has plagued pet owners for decades.

• For Allergy Sufferers: It offers a future where you can hug a cat without needing an EpiPen.
• For Cats: It avoids the risk of deleting a protein that might be essential for the cat's health.
• For Science: It proves that we can "reprogram" nature to be friendly to humans without breaking the animal.

In short, the scientists didn't try to ban the cat; they just taught the cat to speak a language the allergic immune system doesn't understand.

Technical Summary

1. Problem Statement

Cat allergy is a prevalent global health issue, affecting approximately 20% of the population. The primary driver of these allergic reactions is Fel d 1, a heterodimeric glycoprotein found in cat saliva, skin, and fur, which accounts for 90% of feline-induced allergies.

• Limitations of Current Treatments:
  • Avoidance: Often impractical due to the ubiquity of allergens.
  • Symptomatic Relief: Antihistamines and corticosteroids treat symptoms but do not address the underlying IgE-mediated sensitivity.
  • Allergen-Specific Immunotherapy (AIT): While disease-modifying, conventional AIT uses native allergen extracts, posing risks of severe systemic reactions and suffering from variable efficacy and long treatment durations.
  • Gene Editing (Knockout): Recent CRISPR attempts to completely knock out Fel d 1 raise concerns about the unknown physiological functions of the protein and potential long-term biological consequences of its total ablation.
• The Gap: There is a need for a strategy that reduces allergenicity (IgE reactivity) while preserving the protein's structural integrity and potential physiological function, offering a safer path for both immunotherapy and the generation of hypoallergenic cats.

2. Methodology

The authors employed a multi-disciplinary approach combining computational protein design, recombinant protein engineering, ex vivo immunological assays, and CRISPR/Cas9 genome editing.

A. Computational Design & Immunoinformatics

• Structural Template: Used the crystal structure of Fel d 1 (PDB ID: 1ZKR).
• Surface Mapping: Identified surface-exposed residues (solvent accessibility > 20) using DSSP.
• Dual-Epitope Targeting:
  • Mapped known B-cell epitopes (IgE binding sites).
  • Predicted T-cell epitopes (CD4+ MHC-II binding) using the IEDB-recommended method across 27 human HLA class II alleles to ensure broad population coverage.
  • Identified "immunological hotspots" where B-cell and T-cell epitopes overlapped, specifically focusing on Epitope 1 (residues 25–38 on Chain 1).
• Variant Library: Designed 30 single-point mutations (15 per chain) targeting these hotspots to disrupt immune recognition without destabilizing the protein core.

B. Recombinant Protein Production

• Constructed a single-chain fusion of native Chain 1 and Chain 2 (rFel d 1).
• Expressed in E. coli as inclusion bodies.
• Utilized a rapid detergent-based renaturation protocol to refold the protein into its native conformation.
• Purified via Ni-NTA affinity chromatography.

C. Ex Vivo Functional Screening

• IgE Binding Assay: Screened the 30 variants against sera from cat-allergic donors (initially P5 and N7, then expanded to a full cohort of IgE-positive donors) using ELISA.
• Basophil Activation Test (BAT): Evaluated the functional hypoallergenicity of lead candidates. Peripheral blood basophils from allergic donors were sensitized with serum IgE and challenged with wild-type (rFel d 1) or engineered variants. Activation was measured via flow cytometry (CD63 and CD123 surface markers).

D. CRISPR/Cas9 Genome Editing

• Target: Feline fetal fibroblasts.
• Strategy: Introduced the most promising mutation (K29G in Chain 1) using a ribonucleoprotein (RNP) complex and a single-stranded oligodeoxynucleotide (ssODN) donor template.
• Validation: Confirmed the edit via Sanger sequencing.
• Fitness Assessment: Monitored population doubling time (PDT) and morphology of edited cells (passages 8–19) compared to wild-type controls to ensure the mutation did not impair cellular fitness.

3. Key Contributions

1. Dual-Epitope Design Strategy: Unlike previous attempts focusing solely on B-cell epitopes, this study integrated T-cell epitope mapping to target "dual-epitope hotspots," aiming to reduce both IgE binding and T-cell activation potential simultaneously.
2. Identification of K29G: Successfully identified the K29G mutation (Lysine to Glycine at position 29 in Chain 1) as a lead candidate that significantly disrupts IgE binding while maintaining protein stability.
3. Proof-of-Concept for Gene-Edited Hypoallergenic Cats: Demonstrated that the K29G mutation can be successfully introduced into feline cells via CRISPR/Cas9 without compromising cell proliferation or viability, paving the way for generating cats that naturally produce hypoallergenic Fel d 1.

4. Key Results

• Computational & Structural: The analysis confirmed Epitope 1 as a critical hotspot with high overlap between IgE contact residues and predicted MHC-II binding regions.
• IgE Reactivity:
  • The recombinant wild-type (rFel d 1) showed IgE binding comparable to natural Fel d 1.
  • Among the 30 variants, K29G exhibited a profound reduction in IgE reactivity across multiple allergic donors.
  • Other variants (e.g., L31E) showed inconsistent results across different donor sera, highlighting the importance of broad cohort screening.
• Basophil Activation:
  • Wild-type rFel d 1 induced robust basophil activation (high CD63+/CD123+ frequencies).
  • The K29G variant suppressed basophil activation to near-background levels in all tested donors (P2, P3, P8), confirming it effectively abrogates the downstream effector phase of the allergic response.
• Cellular Fitness:
  • CRISPR-edited feline fibroblasts (K29G) showed no sustained growth inhibition or morphological abnormalities compared to wild-type cells over 11 passages.
  • Population doubling times fluctuated similarly in both groups, indicating the mutation does not disrupt fundamental cellular processes.

5. Significance

• Therapeutic Innovation: This work validates a rational, structure-guided approach to creating "hypoallergens" that are safer than native extracts for immunotherapy, potentially reducing the risk of anaphylaxis during treatment.
• Genomic Solution: It provides a critical proof-of-concept for generating genetically edited hypoallergenic cats. By retaining the Fel d 1 protein (rather than knocking it out) but rendering it non-allergenic, this approach theoretically preserves the protein's unknown physiological functions while eliminating the clinical trigger for allergies.
• Translational Feasibility: The successful integration of computational design, recombinant production, and gene editing demonstrates a viable pipeline for addressing complex allergen challenges, moving beyond symptomatic management to source-level allergen mitigation.